Literature DB >> 8626396

Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I response to heparin.

T Arai1, J Clarke, A Parker, W Busby, T Nam, D R Clemmons.   

Abstract

Heparin binding to insulin-like growth factor (IGF)-binding protein 5 (IGFBP-5) leads to a 17-fold decrease in its affinity for IGF-I, and a region that contains several basic amino acids (Arg201-Arg218) may be involved in this affinity shift. In the present study, mutagenesis was used to analyze the effect of substitutions for basic amino acids in the Arg201-Arg218 region of IGFBP-5 on heparin-binding and the heparin-induced affinity shift. Nine mutant forms were prepared. Their association constants (Ka) for IGF-I were similar to native IGFBP-5. When 10 microg/ml of heparin was added, the Ka of native IGFBP-5 decreased 17-fold, and the Ka of the K134A/R136A mutant decreased 16-fold. In contrast, substitutions for specific basic amino acids in the Arg2O1-Arg218 region decrease the affinity shift to 1.1-3.2-fold. Lys 211 was especially important. When a mutant containing that single substitution was tested, heparin caused only a 2.5-fold reduction in IGF-I affinity. Affinity cross-linking studies showed that heparin was equipotent in inhibiting the formation of 125I-IGF-I-K134A/Rl36A mutant complexes compared to native IGFBP-5. In contrast, heparin had minimal effects on the formation of complexes between 125I-IGF-I and the other mutants. The heparin-binding activity of each mutant was determined. Four mutants, R201A/K202N, K202A/K206A/R207A, R201A/K202N/K206N/K208N, and K211N/R214A/K217A/R218A, had reduced heparin binding compared to native IGFBP-5. The other five mutants, including the K21IN mutant, showed no change in heparin binding. The four mutants with reduced heparin binding could be dissociated from heparin-Sepharose with much lower NaCl concentrations, indicating that they had reduced affinity. These findings suggest that Arg201 Lys202, LysS206, and Arg214 are important for heparin binding. In contrast, LyS211 is not important for the binding of IGFBP-5 to heparin, but substitution for it reduced the heparin-induced affinity shift.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8626396     DOI: 10.1074/jbc.271.11.6099

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Differential effect of fasting on IGF-BPs in serum of young and adult rats and its implication to impaired skin GAG content.

Authors:  M Cechowska-Pasko; J Pałka
Journal:  Mol Cell Biochem       Date:  2000-02       Impact factor: 3.396

2.  IGFBP-2 - taking the lead in growth, metabolism and cancer.

Authors:  Steven W Yau; Walid J Azar; Matthew A Sabin; George A Werther; Vincenzo C Russo
Journal:  J Cell Commun Signal       Date:  2015-01-25       Impact factor: 5.782

3.  Binding of insulin-like growth factor (IGF)-binding protein-5 to smooth-muscle cell extracellular matrix is a major determinant of the cellular response to IGF-I.

Authors:  A Parker; C Rees; J Clarke; W H Busby; D R Clemmons
Journal:  Mol Biol Cell       Date:  1998-09       Impact factor: 4.138

4.  Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions.

Authors:  W Kalus; M Zweckstetter; C Renner; Y Sanchez; J Georgescu; M Grol; D Demuth; R Schumacher; C Dony; K Lang; T A Holak
Journal:  EMBO J       Date:  1998-11-16       Impact factor: 11.598

5.  Duplicated zebrafish insulin-like growth factor binding protein-5 genes with split functional domains: evidence for evolutionarily conserved IGF binding, nuclear localization, and transactivation activity.

Authors:  Wei Dai; Hiroyasu Kamei; Yang Zhao; Jun Ding; Zhou Du; Cunming Duan
Journal:  FASEB J       Date:  2010-01-15       Impact factor: 5.191

6.  Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture.

Authors:  Y Imai; W H Busby; C E Smith; J B Clarke; A J Garmong; G D Horwitz; C Rees; D R Clemmons
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

7.  Insulin-like growth factor (IGF) binding protein-5 blocks skeletal muscle differentiation by inhibiting IGF actions.

Authors:  Aditi Mukherjee; Elizabeth M Wilson; Peter Rotwein
Journal:  Mol Endocrinol       Date:  2007-09-20

Review 8.  Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis.

Authors:  James Beattie; Gordon J Allan; Jennifer D Lochrie; David J Flint
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

9.  Insulin-like growth factor binding proteins: a structural perspective.

Authors:  Briony E Forbes; Peter McCarthy; Raymond S Norton
Journal:  Front Endocrinol (Lausanne)       Date:  2012-03-02       Impact factor: 5.555

10.  Pitavastatin Regulates Ang II Induced Proliferation and Migration via IGFBP-5 in VSMC.

Authors:  Yu Mi Ha; Ju-Ock Nam; Young Jin Kang
Journal:  Korean J Physiol Pharmacol       Date:  2015-10-16       Impact factor: 2.016

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.